Promising results for trial looking at olaparib in combination with bevacizumab as first line treatment

News from the ESMO (European Society for Medical Oncology) 2019 conference: promising results for trial looking at olaparib in combination with bevacizumab as first line treatment.

Comments (0)

Comment (maximum 3500 characters) *

Add a picture

Notify me when someone makes a comment

First name *

Last name *

Email *

Which country do you live in?

Please enter your postcode*

Address line 1

Address line 2

Town or city

Keeping In Touch

We'd love to keep you posted with our news, activities and how you can help in other ways. We'll never sell or swap your details with anybody else. You are free to change your mind at anytime. Please indicate how you would like to hear from us by using the tick boxes below

Via email

Via telephone

Via SMS

Via post

Which country do you live in?

Please enter your postcode*

Address line 1

Address line 2

Town or city

Your Privacy

We will always store your personal details securely. We'll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy

By submitting this form you are agreeing to our terms and conditions

Latest

Diet and cancer: a guide to eating well

Specialist oncology dietitian Rachel White will be answering your questions about diet and cancer.
Exercising for health during and after treatment: a stay at home guide

Cancer Exercise Specialist Lizzy Davis will be letting you know how you can exercise while staying at home.
Employment rights for people with cancer

Victoria Von Wachter, a barrister specialising in employment and discrimination law, will be running a Q&A workshop to answer your questions.
Keep Active

Stay healthy and create your own solo sponsored run or walk.